Clinical trial
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial…
NCT00220402 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00220402 |
|---|---|
| Title | Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome |
| Official title | Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Overactive Bladder Syndrome |
| Intervention type | Drug |
| Interventions | SPM 907 |
| Start date | Jul 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 24, 2008 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: